See more : Alfa Laval AB (publ) (ALFVY) Income Statement Analysis – Financial Results
Complete financial analysis of OBI Pharma, Inc. (4174.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of OBI Pharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- CPH Chemie + Papier Holding AG (CPHN.SW) Income Statement Analysis – Financial Results
- McKesson Corporation (MCK) Income Statement Analysis – Financial Results
- CION Investment Corporation (CION) Income Statement Analysis – Financial Results
- Kanagawa Chuo Kotsu Co., Ltd. (9081.T) Income Statement Analysis – Financial Results
- Gexeed Co., Ltd. (3719.T) Income Statement Analysis – Financial Results
OBI Pharma, Inc. (4174.TWO)
About OBI Pharma, Inc.
OBI Pharma, Inc., a biopharma company, develops and licenses novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. It offers Adagloxad Simolenin (OBI-822), a breast cancer active immunity anti-cancer drug for generating antibody against tumor carbohydrate antigen Globo H; OBI-833, an immunity anti-cancer drug for the treatment of lung cancer; OBI-866 SSEA-4, an active immune-oncology drug; OBI-888, a passive immunotherapy monoclonal antibody designed for targeting Globo H; OBI-999, an antibody drug conjugate; OBI-3424, a micromolecule chemotherapy prodrug; and OBI-858, a botulinum toxin, as well as OBI-898 and OBI-998 drugs. The company was founded in 2002 and is headquartered in Taipei, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 41.55M | 4.71M | 18.77M | 140.89M | 872.00K | 13.34M | 376.00K | 92.42M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 115.05M | 44.86M | 44.36M | 6.47M | 226.33M | 5.29M | 67.27M | 45.43M | 33.43M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -73.50M | -40.14M | -25.59M | 134.42M | -225.46M | 8.05M | -66.90M | 46.99M | -33.43M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | -176.89% | -852.13% | -136.32% | 95.41% | -25,854.93% | 60.37% | -17,791.22% | 50.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.70B | 1.77B | 1.45B | 1.31B | 1.18B | 1.13B | 848.73M | 859.48M | 648.16M | 485.29M | 345.48M | 193.17M | 99.44M |
| General & Administrative | 319.28M | 309.76M | 240.83M | 290.42M | 267.54M | 308.65M | 341.29M | 345.41M | 415.06M | 227.04M | 122.17M | 90.94M | 42.20M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 319.28M | 309.76M | 240.83M | 290.42M | 267.54M | 308.65M | 341.29M | 345.41M | 415.06M | 227.04M | 122.17M | 90.94M | 42.20M |
| Other Expenses | 0.00 | 159.73M | -28.90M | -67.04M | 8.39M | 173.55M | -186.61M | 5.06M | 123.41M | 45.32M | 29.07M | 24.66M | 15.95M |
| Operating Expenses | 2.02B | 2.08B | 1.69B | 1.60B | 1.45B | 1.44B | 1.19B | 1.20B | 1.06B | 712.33M | 467.65M | 284.10M | 141.64M |
| Cost & Expenses | 2.13B | 2.13B | 1.73B | 1.61B | 1.45B | 1.44B | 1.19B | 1.20B | 1.06B | 712.33M | 467.65M | 284.10M | 141.64M |
| Interest Income | 92.96M | 49.93M | 6.46M | 43.42M | 93.39M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.29M | 339.00K |
| Interest Expense | 7.94M | 3.99M | 3.80M | 4.18M | 2.71M | 1.67M | 1.20M | 213.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 248.95M | 246.61M | 216.28M | 231.84M | 213.90M | 122.61M | 67.27M | 45.43M | 33.43M | 24.46M | 16.19M | 16.27M | 5.65M |
| EBITDA | -855.09M | -1.67B | -1.52B | -1.26B | -1.50B | -1.13B | -1.31B | -1.06B | -906.38M | -687.87M | -451.46M | -235.66M | -91.29M |
| EBITDA Ratio | -2,058.02% | -35,374.49% | -8,108.78% | -892.68% | -146,221.90% | -8,482.78% | -348,134.04% | -1,149.06% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -2.09B | -1.91B | -1.74B | -1.49B | -1.44B | -1.43B | -1.19B | -1.11B | -1.06B | -712.33M | -467.65M | -284.10M | -141.64M |
| Operating Income Ratio | -5,029.70% | -40,609.25% | -9,260.89% | -1,057.24% | -165,421.22% | -10,703.07% | -316,394.15% | -1,203.69% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 814.24M | 205.67M | -26.24M | -27.81M | -143.47M | 171.88M | -187.82M | 4.85M | 123.41M | 45.32M | 29.07M | 28.83M | 14.05M |
| Income Before Tax | -1.28B | -1.92B | -1.74B | -1.49B | -1.45B | -1.26B | -1.38B | -1.11B | -939.81M | -667.01M | -438.58M | -255.28M | -127.59M |
| Income Before Tax Ratio | -3,070.00% | -40,693.95% | -9,281.13% | -1,060.21% | -165,731.77% | -9,414.51% | -366,344.95% | -1,198.44% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -9.59M | -17.77M | -24.36M | -3.79M | -5.59M | -6.31M | 1.98M | 2.50M | 1.52M | 0.00 | 0.00 | -3.34M | 2.52M |
| Net Income | -1.05B | -1.90B | -1.72B | -1.49B | -1.44B | -1.22B | -1.38B | -1.11B | -941.34M | -667.01M | -438.58M | -255.28M | -127.59M |
| Net Income Ratio | -2,518.65% | -40,316.79% | -9,151.34% | -1,057.52% | -165,090.60% | -9,162.92% | -366,871.28% | -1,201.15% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -4.54 | -8.55 | -8.55 | -7.43 | -7.43 | -7.06 | -7.91 | -6.39 | -5.55 | -4.46 | -3.11 | -1.95 | -1.35 |
| EPS Diluted | -4.54 | -8.55 | -8.55 | -7.43 | -7.43 | -6.99 | -7.91 | -6.39 | -5.55 | -4.38 | -3.05 | -1.92 | -1.35 |
| Weighted Avg Shares Out | 230.41M | 222.13M | 200.95M | 200.60M | 193.71M | 173.08M | 174.42M | 173.76M | 169.48M | 149.57M | 140.95M | 130.74M | 94.69M |
| Weighted Avg Shares Out (Dil) | 230.41M | 222.13M | 200.95M | 200.60M | 193.71M | 174.83M | 174.42M | 173.76M | 169.48M | 152.44M | 143.65M | 133.24M | 94.69M |
Source: https://incomestatements.info
Category: Stock Reports